We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
+12.71%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.43B
AUM Growth
+$322M
(+29%)
Cap. Flow
+$229M
Cap. Flow
% of AUM
16.07%
Top 10 Holdings %
Top 10 Hldgs %
6.36%
Holding
2,241
New
645
Increased
572
Reduced
474
Closed
546
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$13.4M |
| 2 |
NVIDIA
NVDA
|
+$12.7M |
| 3 |
Microsoft
MSFT
|
+$11.3M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$8.44M |
| 5 |
JPMorgan Chase
JPM
|
+$6.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CSX Corp
CSX
|
+$4.12M |
| 2 |
Blackstone
BX
|
+$3.99M |
| 3 |
KLG
WK Kellogg Co
KLG
|
+$3.21M |
| 4 |
Cal-Maine
CALM
|
+$2.92M |
| 5 |
Frontline
FRO
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.54% |
| 2 | Financials | 15.47% |
| 3 | Healthcare | 14.21% |
| 4 | Industrials | 11.6% |
| 5 | Consumer Discretionary | 11.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Karyopharm Therapeutics
KPTI
$48M
| $60K | ﹤0.01% |
+13,894
| New | +$68.2K |
|
1652
AEye
LIDR
$61.1M
| $60K | ﹤0.01% |
58,079
-3,416
| -6% | -$2.45K |
|
1653
Myriad Genetics
MYGN
$312M
| $60K | ﹤0.01% |
+11,215
| New | +$66.2K |
|
1654
Lexeo Therapeutics
LXEO
$378M
| $58K | ﹤0.01% |
+14,528
| New | +$47.8K |
|
1655
Prelude Therapeutics
PRLD
$390M
| $58K | ﹤0.01% |
+71,378
| New | +$61.8K |
|
1656
W&T Offshore
WTI
$518M
| $58K | ﹤0.01% |
+35,031
| New | +$51.6K |
|
1657
Quince Therapeutics
QNCX
$29.5M
| $56K | ﹤0.01% |
169
-14
| -8% | -$3.2K |
|
|
ISPO
1658
DELISTED
Inspirato
ISPO
| $54K | ﹤0.01% |
+15,903
| New | +$58.4K |
|
1659
Ceragon Networks
CRNT
$201M
| $53K | ﹤0.01% |
+21,550
| New | +$49.2K |
|
|
OKUR
1660
OnKure Therapeutics
OKUR
$168M
| $52K | ﹤0.01% |
+21,765
| New | +$57.1K |
|
1661
SelectQuote
SLQT
$121M
| $50K | ﹤0.01% |
+20,946
| New | +$55K |
|
|
OLPX
1662
DELISTED
Olaplex Holdings
OLPX
| $49K | ﹤0.01% |
34,935
-695,536
| -95% | -$906K |
|
1663
Vuzix
VUZI
$224M
| $47K | ﹤0.01% |
16,059
-129,023
| -89% | -$304K |
|
1664
InflaRx
IFRX
$271M
| $46K | ﹤0.01% |
+57,951
| New | +$68.5K |
|
1665
OmniAb
OABI
$447M
| $46K | ﹤0.01% |
26,174
-99,278
| -79% | -$166K |
|
1666
HF Foods Group
HFFG
$83.4M
| $44K | ﹤0.01% |
+13,957
| New | +$53.2K |
|
1667
Perfect Corp
PERF
$196M
| $44K | ﹤0.01% |
19,302
-4,299
| -18% | -$7.94K |
|
1668
Atossa Therapeutics
ATOS
$23.5M
| $42K | ﹤0.01% |
+3,402
| New | +$40.7K |
|
1669
Rimini Street
RMNI
$471M
| $40K | ﹤0.01% |
+10,718
| New | +$35.8K |
|
1670
Hain Celestial
HAIN
$53.7M
| $39K | ﹤0.01% |
25,636
-292,690
| -92% | -$684K |
|
|
TSE
1671
DELISTED
Trinseo
TSE
| $39K | ﹤0.01% |
12,450
-92,622
| -88% | -$305K |
|
|
ASRT
1672
DELISTED
Assertio
ASRT
| $38K | ﹤0.01% |
+4,000
| New | +$38.4K |
|
1673
Aterian
ATER
$5.37M
| $38K | ﹤0.01% |
+23,095
| New | +$39.3K |
|
1674
Acumen Pharmaceuticals
ABOS
$176M
| $37K | ﹤0.01% |
+32,103
| New | +$34.5K |
|
1675
PLAYSTUDIOS Inc
MYPS
$90.1M
| $37K | ﹤0.01% |
+27,971
| New | +$38.4K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q2 2025 Portfolio in Review
As of Q2 2025, GSA Capital Partners held 2,241 positions worth $1.43B, up 29% from $1.11B the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.
GSA Capital Partners deployed $229M of net new capital in Q2 2025, opening 645 new positions and adding to 572 existing holdings. Its largest new stake was Berkshire Hathaway Class B: 16,625 shares worth $8.08M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was CSX Corp, an estimated $4.12M trimmed.
- GSA Capital Partners's largest Q2 2025 buy was Berkshire Hathaway Class B: 16,625 shares worth $8.08M.
- GSA Capital Partners added most to Apple in Q2 2025, an estimated $13.4M increase.
- GSA Capital Partners's biggest Q2 2025 reduction was CSX Corp, cutting an estimated $4.12M.
- GSA Capital Partners fully exited WK Kellogg Co in Q2 2025, selling an estimated $3.21M.
- GSA Capital Partners's ten largest holdings make up 6.4% of its $1.43B portfolio in Q2 2025.
- GSA Capital Partners opened 645 new positions and closed 546 in Q2 2025.
- GSA Capital Partners's portfolio value rose 29% quarter-over-quarter to $1.43B.
Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.